Novel cancer-associated secretory cells and IL-1β+ macrophages as key players in early lung adenocarcinoma progression in female never-smokers

Junsu Choe; Jinyeong Lim; Noeul Kang; Eun Seop Seo; Mina Hwang; Kyung Yeon Han; Se-Hoon Lee; Myung-Ju Ahn; Yoon-La Choi; Hong Kwan Kim; Woong-Yang Park; Sang-Won Um

doi:10.1002/ctm2.70433

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (8) :e70433 DOI: 10.1002/ctm2.70433

LETTER TO THE JOURNAL

Novel cancer-associated secretory cells and IL-1β⁺ macrophages as key players in early lung adenocarcinoma progression in female never-smokers

Author information +

¹. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

². Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

³. Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁴. Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea

⁵. Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁶. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁷. Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

hkts@skku.edu

woongyang@skku.edu

sangwonum@skku.edu

Show less

History +

PDF

Cite this article

Download citation ▾

Junsu Choe, Jinyeong Lim, Noeul Kang, Eun Seop Seo, Mina Hwang, Kyung Yeon Han, Se-Hoon Lee, Myung-Ju Ahn, Yoon-La Choi, Hong Kwan Kim, Woong-Yang Park, Sang-Won Um. Novel cancer-associated secretory cells and IL-1β⁺ macrophages as key players in early lung adenocarcinoma progression in female never-smokers. Clinical and Translational Medicine, 2025, 15(8): e70433 DOI:10.1002/ctm2.70433

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015; 10(9): 1243-1260.

[2]	Kim N, Kim HK, Lee K, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020; 11(1): 2285.

[3]	Zhang P, He B, Cai Q, et al. Decreased IL-6 and NK cells in early-stage lung adenocarcinoma presenting as ground-glass opacity. Front Oncol. 2021; 11: 705888.

[4]	Li R, Ong SL, Tran LM, et al. Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Sci Rep. 2020; 10(1): 377.

[5]	Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390(10105): 1833-1842.

[6]	Caronni N, La Terza F, Vittoria FM, et al. IL-1β(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023; 623(7986): 415-422.

[7]	Xu L, Lu C, Huang Y, et al. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker. BMB Rep. 2018; 51(12): 648-653.

[8]	Zhang X, Han X, Zuo P, Zhang X, Xu H. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. J Int Med Res. 2020; 48(9): 300060520959478.

[9]	Kim EY, Cha YJ, Jeong S, Chang YS. Overexpression of CEACAM6 activates Src-FAK signaling and inhibits anoikis, through homophilic interactions in lung adenocarcinomas. Transl Oncol. 2022; 20: 101402.

[10]	ClinicalTrials.gov. Study of BAY1834942 in Patients with Solid Tumors. Clinical Trial Registration NCT03596372. 2022. Accessed December 29, 2024. https://clinicaltrials.gov/study/NCT03596372

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.